#United States #DAV #Psychedelic Therapy #Ibogaine #Erlanger, Kentucky

DAV and Americans for Ibogaine Join Forces for Veteran Support

On May 11, 2026, a significant partnership was announced between Disabled American Veterans (DAV) and Americans for Ibogaine, marking a pivotal moment for veterans seeking new treatment options. This collaboration focuses on advancing education, research, and advocacy related to emerging psychedelic therapies, particularly ibogaine, which shows promise in treating addiction and trauma-related conditions, including PTSD and other brain injuries.

Understanding the Collaboration

The initiative reflects DAV’s longstanding commitment to improving veterans’ access to alternative health solutions and Americans for Ibogaine’s mission to reform policies surrounding psychedelic treatments. By merging resources and expertise, both organizations aim to foster a comprehensive understanding of ibogaine’s benefits and potential medical applications.

Barry Jesinoski, the CEO of DAV, spoke passionately about the need for innovative solutions tailored to veterans’ unique health challenges, emphasizing how crucial it is for them to have access to credible information and continual research. He stated, “Veterans are seeking new solutions to complex health challenges, particularly in areas related to brain injuries, PTSD, and substance use disorder.”

What is Ibogaine?

Ibogaine is a naturally occurring psychoactive compound that has garnered attention for its potential in transforming the lives of individuals struggling with addiction and trauma. Despite its non-approval at the federal level for medical use, momentum is building at the state level, with various initiatives aiming to promote research and therapeutic access.

Goals of the Partnership

Through this partnership, DAV and Americans for Ibogaine are committed to:

• - Educational Resource Development: Providing science-based resources grounded in the experiences of veterans.
• - Highlighting Research: Keeping the public informed about ongoing research initiatives and legislative developments in the field of psychedelic therapy.
• - Mobilizing Advocacy: Energizing DAV members to advocate for evidence-based ibogaine research and treatment options in legislative assemblies across the nation.
• - Promoting Veteran Voices: Elevating the personal experiences of veterans to inform and enrich discussions surrounding these emerging therapies.
• - Encouraging Responsible Exploration: Supporting a veteran-centered approach to exploring the potential benefits of these novel therapies.

Bryan Hubbard, the CEO of Americans for Ibogaine, echoed Jesinoski's sentiments, underscoring the critical need for accessible treatment options for veterans who often face barriers in their own country. He stated, “Veterans have been forced to leave the nation they served in to access ibogaine treatment when all other options have failed.”

Continuing Advocacy by DAV

DAV has historically been at the forefront of advocating for innovative treatments for veterans. They have consistently pushed for the exploration of psychedelic-assisted therapies within the Department of Veterans Affairs, reflecting a broader commitment to utilizing all available approaches to support veterans’ health and well-being.

Conclusion

The alliance between DAV and Americans for Ibogaine represents a forward-thinking approach to tackling veterans’ mental health obstacles using evidence-based therapies. As they work together to advocate and educate, both organizations hope to pave the way for effective treatments that can ultimately transform the lives of countless veterans in need. For more information on this partnership and available resources, visit DAV.org and AmericansForIbogaine.org.

• ---